Table 4.
Live attenuated heterologous vaccine candidates: Protection against SCHU S4 respiratory challenge.
| Prime vaccine | Host strain | Prime route, dose (CFU) | Boost (vaccine, route)a | LVS control (route)b | Interval (days)c | SCHU S4 challenge route, dose (LD50) | % Survival post-challenge (MST, days)d | References | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine | LVS | Sham | ||||||||
| HETEROLOGOUS STANDALONE VACCINES | ||||||||||
| Lm ΔactA (LmV) |
BALB/c | i.d., 106 | Yes (LmV × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 1 | 38 | 88 | 50 | Jia et al., 2009 |
| i.d., 106 | Yes (LmV × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 10 | 38 | 88 | 0 | Jia et al., 2009 | ||
| rLm/iglC | BALB/c | i.d., 106 | Yes (rLm/iglC × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 1 | 100 | 88 | 50 | Jia et al., 2009 |
| i.d., 106 | Yes (rLm/iglC × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 10 | 75 | 88 | 0 (6) | Jia et al., 2009 | ||
| rLm/katG | BALB/c | i.d., 106 | Yes (rLm/katG × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 1 | 88 | 88 | 50 | Jia et al., 2009 |
| i.d., 106 | Yes (rLm/katG × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 10 | 25 | 88 | 0 (6) | Jia et al., 2009 | ||
| HOMOLOGOUS PRIME AND HETEROLOGOUS BOOST VACCINES | ||||||||||
| LVS ΔcapB | BALB/c | i.d., 106 | Yes (rLm/iglC × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 10 | 75 (19) | 63 (17) | 0 (5) | Jia et al., 2013 |
| rLVS ΔcapB /IglC |
BALB/c | i.d., 106 | Yes (rLm/iglC × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 10 | 75 (20) | 63 (17) | 0 (5) | Jia et al., 2013 |
| rLVS ΔLPS /IglC |
BALB/c | i.d., 106 | Yes (rLm/iglC × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 3 | 63 (16) | 100 (21) | 0 (4) | Jia et al., 2013 |
| rLVS ΔLPS /IglC |
BALB/c | i.d., 106 | Yes (rLm/iglC × 2, i.d.) | Yes (i.d.) | 42 | Aerosol, 3 | 100 (21) | 100 (21) | 0 (4) | Jia et al., 2013 |
| rLVS ΔLPS /IglC |
BALB/c | i.d., 106 | Yes (rLm/iglC × 1, i.d.) | Yes (i.d.) | 42 | Aerosol, 10 | 38 (11) | 100 (21) | 0 (4) | Jia et al., 2013 |
| rLVS ΔLPS /IglC |
BALB/c | i.d., 106 | Yes (rLm/iglC × 2, i.d.) | Yes (i.d.) | 42 | Aerosol, 10 | 63 (15) | 100 (21) | 0 (4) | Jia et al., 2013 |
Boost: Heterologous standalone vaccines: mice were primed at Week 0 and boosted once (× 1) at Week 4 with Lm vector (LmV) or LmV expressing F. tularensis IglC (rLm/iglC) or KatG (rLm/katG); Homologous prime and heterologous boost vaccines: mice were primed at Week 0 with LVS ΔcapB or LVS ΔcapB overexpressing IglC (rLVS ΔcapB/IglC) or LVS ΔLPS overexpressing IglC (rLVS ΔLPS/IglC), and boosted with rLm/iglC once (× 1) at Week 4 or twice (× 2) at Weeks 3 and 6.
LVS control: in heterologous standalone vaccine studies, LVS was given i.d. twice at Weeks 0 and 4; in homologous prime-heterologous boost studies, LVS was given once at Week 4.
Interval: Time between the only or the last immunization and the challenge.
Survival, % survival after challenge of mice immunized with the vaccine candidate (vaccine), LVS control (LVS), or no vaccine or PBS control (Sham). MST: Mean Survival Time.